Samsung Bioepis’ Q1 biosimilar sales in Europe hit $205m - (The Korea Herald via NewsPoints Desk)

  • Sales of biosimilars developed by Samsung Bioepis in Europe reached $205.1 million in the first quarter this year, The Korea Herald reported on Friday.

  • Sales of the company’s three major autoimmune biosimilars -- Benepali, Flixabi and Imraldi -- increased 3.9% on-quarter but decreased 6.3% on-year, the company said, citing an earnings report that its partner Biogen released on Thursday.

  • "There was a sudden jump in sales during the first quarter last year as hospitals and wholesalers in Europe tried to stockpile products amid the COVID-19 pandemic," a company official said, explaining the on-year decrease.

  • Samsung Bioepis said that Benepali accounted for the largest share in the European market by sales at 44%, while Flixabi and Imraldi each accounted for over 10% in market share.

To read more NewsPoints articles, click here.

Reference Articles